Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Triveni Bio
Triveni Bio

Triveni Bio

Series C

Triveni Bio develops first-in-class antibody therapeutics for immunological and inflammatory disorders using a genetics-informed approach.

HQ
Watertown, MA, US
Founded
2023
Overview
Compare
Fundraising
Employees
News

Triveni Bio is a clinical-stage biotechnology company developing novel antibody therapeutics for immunological and inflammatory (I&I) disorders. It combines a Mendelian genetics-informed precision medicine approach with advanced antibody engineering to identify targets and build functional antibodies. Its pipeline includes TRIV-509, a dual kallikreins 5 and 7 inhibitor in Phase 2 for atopic dermatitis; TRIV-573, a bispecific antibody targeting KLK5/7 and interleukin 13; and TRIV-920, a first-in-class dual trypsin 1 and 2 inhibitor in preclinical development for pancreatitis.

Founded in 2023 through the merger of Amagma Therapeutics and Modify Therapeutics, Triveni Bio is headquartered in Watertown, Massachusetts. The company has raised over $272 million across three funding rounds, including a $92 million Series A, a $115 million Series B, and a $65 million Series C co-led by Ascenta Capital and Janus Henderson Investors in June 2026. Triveni Bio is led by CEO Vishal Patel, PhD, Chief Medical Officer Bhaskar Srivastava, MD, PhD, and Chief Scientific Officer Jennifer Dovey, PhD.

Triveni Bio - Products & Services

  • TRIV-920 logo

    TRIV-920

    TRIV-920 is a first-in-class monoclonal antibody in preclinical development for the treatment of pancreatitis.

  • TRIV-509 logo

    TRIV-509

    A half-life extended monoclonal antibody targeting kallikreins 5 and 7, in Phase 2 proof-of-concept trial for atopic dermatitis.

  • TRIV-573 logo

    TRIV-573

    A first-in-class bispecific antibody targeting kallikreins 5 and 7 and interleukin 13, in Phase 1 clinical trials for atopic dermatitis.

Triveni Bio - Similar Companies

Dren Bio logo

Dren Bio

drenbio.com

Tr1x logo

Tr1x

tr1x.bio

Trancura Biosciences logo

Trancura Biosciences

GentiBio logo

GentiBio

gentibio.com

Therini Bio logo

Therini Bio

therinibio.com

TRex Bio logo

TRex Bio

trex.bio

EpiBiologics logo

EpiBiologics

epibiologics.com

Global Bio logo

Global Bio

Upstream Bio logo

Upstream Bio

upstreambio.com

iBio logo

iBio

ibioinc.com

Zebra Biologics logo

Zebra Biologics

Trinity Biosystems logo

Trinity Biosystems

Santa Ana Bio logo

Santa Ana Bio

santaanabio.com

Proteinea logo

Proteinea

proteinea.com

Traverse Biosciences logo

Traverse Biosciences

Triveni Bio - Quick Facts

Who are Triveni Bio's competitors?

Companies similar to Triveni Bio include Dren Bio, Tr1x, Trancura Biosciences and GentiBio.

When was Triveni Bio founded?

Triveni Bio was founded in 2023.

Where is Triveni Bio's headquarters located?

Triveni Bio's headquarters is located in Watertown, MA, US.

When was Triveni Bio's last funding round?

Triveni Bio's most recent funding round was for $65M (USD) in June 2026.

How much has Triveni Bio raised to-date?

As of Jun 17, 2026, Triveni Bio has raised a total of $272M (USD).

How many employees does Triveni Bio have?

Triveni Bio has 6 employees as of Feb 4, 2024.

Triveni Bio - Classification

Industry
  • Biotechnology Companies
Ownership
  • Private
  • Venture-backed private company
  • Venture Capital
Technology
  • AI
  • Antibody Engineering
  • Biotech
Geographic Exposure
  • United States
Model
  • Research Lab
Revenue
  • Pre-Revenue
Customer
  • Enterprise
Tags
  • Biotech
  • Data
  • Healthtech
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
Show 8 more industry codes
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research